
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics is expected to have a positive future due to the potential approval of deramiocel for the treatment of DMD cardiomyopathy. The recent data presented at the MDA conference showed improvements in cardiac function, reduction of myocardial fibrosis, and slowing of disease progression. With the possibility of PRV and FDA approval, Capricor's market value is likely to increase significantly, making it a favorable investment option.
Bears say
Capricor Therapeutics is facing legal uncertainty with NS, which may increase stock volatility; however, the company's primary focus remains on preparing for Deramiocel's FDA approval and commercial launch. Despite the lawsuit with NS, Capricor has continued to advance Deramiocel through Phase 3 clinical development and has ramped up pre-launch efforts independently. There is potential for stock growth through the company's promising HOPE-3 data, but risks remain, including possible failed trials or funding challenges.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares